share_log

Acumen Pharmaceuticals Collaborates With Lonza Covering The Manufacture Of Sabirnetug (ACU193) For Alzheimer's Disease, For Clinical Development And Commercialization, If Approved

Acumen Pharmaceuticals Collaborates With Lonza Covering The Manufacture Of Sabirnetug (ACU193) For Alzheimer's Disease, For Clinical Development And Commercialization, If Approved

如果獲得批准，Acumen Pharmicals與Lonza合作，涵蓋用於阿爾茨海默氏病的Sabirnetug（ACU193）的製造，用於臨床開發和商業化
Benzinga ·  04/04 20:03

Acumen Pharmaceuticals Collaborates With Lonza Covering The Manufacture Of Sabirnetug (ACU193) For Alzheimer's Disease, For Clinical Development And Commercialization, If Approved

如果獲得批准，Acumen Pharmicals與Lonza合作，涵蓋用於阿爾茨海默氏病的Sabirnetug（ACU193）的製造，用於臨床開發和商業化

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論